Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1421340
This article is part of the Research Topic The Growing Role of Immunotherapy and Combination Strategies in Pancreatic and Hepatobiliary Cancers View all 3 articles

Combinations of immune checkpoint inhibitor, chemotherapy, and hyperthermia therapy avoid lymphatic recurrence in cholangiocarcinoma

Provisionally accepted
Heng-Jui Chang Heng-Jui Chang 1*Chiao-Hsu Ke Chiao-Hsu Ke 2Yu -Shan Wang Yu -Shan Wang 3*
  • 1 Department of Radiation Oncology, Wesing Surgery Hospital, Kaohsiung, Taiwan
  • 2 Department of Chemical Engineering and Biotechnology, College of Engineering, National Taipei University of Technology, Taipei, Taiwan
  • 3 Department of Veterinary Medicine, School of Veterinary Medicine, College of Bioresources and Agriculture, National Taiwan University, Taipei, Taiwan

The final, formatted version of the article will be published soon.

    Cholangiocarcinoma is a malignancy known for its aggressiveness and limited treatment options. The malignant tumor behaviors include intrahepatic recurrence, regional lymph node (LN) metastasis, peritoneal carcinomatosis, and lung metastasis.Herein, we reported a case of lymphatic recurrence in an intrahepatic cholangiocarcinoma patient after surgery, adjuvant concurrent chemoradiotherapy (CCRT), who experienced a remarkable response to a combination therapy. However, the patient failed to undergo radiotherapy or other invasive local therapy and therefore received Opdivo (nivolumab) in combination with chemotherapy (FOLFOX) and modulated electro-hyperthermia. Notably, after these medical interventions, this patient had a complete response (CR) to treatments, in which no lymph node metastasis occurred, and a significantly decreased tumor marker, CA 19-9, level was found. This case highlights the potential of multiple anti-tumor therapies, including immune checkpoint inhibitors, chemotherapy, and hyperthermia, in managing challenging cholangiocarcinoma cases.

    Keywords: Immune checkpoint inhibitor, hyperthermia, modulated electro-hyperthermia, Cholangiocarcinoma, Immunotherapy

    Received: 22 Apr 2024; Accepted: 08 Oct 2024.

    Copyright: © 2024 Chang, Ke and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Heng-Jui Chang, Department of Radiation Oncology, Wesing Surgery Hospital, Kaohsiung, Taiwan
    Yu -Shan Wang, Department of Veterinary Medicine, School of Veterinary Medicine, College of Bioresources and Agriculture, National Taiwan University, Taipei, 10617, Taiwan

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.